LUNAPHORE
17.6.2021 17:02:03 CEST | Business Wire | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Dr. Carlo Bifulco, an expert in Translational Molecular Pathology and Pathology Informatics, to its Scientific Advisory Board (SAB) to provide strategic advisory support to the company’s scientific activities and product portfolio development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210617005459/en/
Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC) and is co-Chair of the SITC Pathology Task convened to establish multiplexed immunohistochemistry/immunofluorescence (mIHC/IF) standards.
His current translational research is focused on supporting the characterization of the tumor immune microenvironment through immunohistochemical and image analysis techniques, and on the integration of genomics in immuno-oncology.
Dr. Bifulco’s role in the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of histopathological samples and to support the company in the establishment of scientific partnerships with key stakeholders in coming years.
“We are very excited to have Dr. Bifulco join us as we seek to bring our microfluidic-based platforms to the next-level.” noted Dr. Dupouy, CTO at Lunaphore. “Dr. Bifulco is an innovative Pathologist, whose insights will be invaluable for Lunaphore to harness the potential of multiplexed immunofluorescence in the field of translational research as well as to provide us with a better understanding of US-focused clinical practices, even more so in this era of cancer immunotherapy”.
“I am very excited by Lunaphore’s microfluidic technological advances, aiming to improve speed, reliability, reproducibility and accuracy of tissue-based biomarker testing”, said Dr. Bifulco. “Physician decision-making in personalized medicine needs robust biomarkers, and solutions such as Lunaphore’s Fast-Fluidic Exchange (FFeX) may become instrumental to improving patient outcomes”.
Dr. Bifulco currently serves as the Director of Molecular Pathology and Pathology Informatics at Providence, and as the Director of Translational Molecular Pathology and Molecular Genomics at the Earle A. Chiles Research Institute in Portland, Oregon, a division of the Providence Cancer Institute. He oversees the Province System Molecular Genomics Laboratory, one of the largest clinical genomics labs in the Pacific Northwest, which provides state-of-the-art genomic sequencing to cancer patients across the seven-state system. Prior to joining Providence, Dr. Bifulco served on the Pathology faculty at the National Cancer Center in Milan, at the University of Florida and at Yale University, and completed fellowships in Hematopathology at Yale and in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005459/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom